ZA201701330B - Use of cysteamine in treating infections caused by yeasts / moulds - Google Patents

Use of cysteamine in treating infections caused by yeasts / moulds

Info

Publication number
ZA201701330B
ZA201701330B ZA2017/01330A ZA201701330A ZA201701330B ZA 201701330 B ZA201701330 B ZA 201701330B ZA 2017/01330 A ZA2017/01330 A ZA 2017/01330A ZA 201701330 A ZA201701330 A ZA 201701330A ZA 201701330 B ZA201701330 B ZA 201701330B
Authority
ZA
South Africa
Prior art keywords
cysteamine
yeasts
moulds
infections caused
treating infections
Prior art date
Application number
ZA2017/01330A
Inventor
Deborah O¿Neil
Vanessa Duncan
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of ZA201701330B publication Critical patent/ZA201701330B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
ZA2017/01330A 2014-09-22 2017-02-22 Use of cysteamine in treating infections caused by yeasts / moulds ZA201701330B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
ZA201701330B true ZA201701330B (en) 2018-04-25

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/01330A ZA201701330B (en) 2014-09-22 2017-02-22 Use of cysteamine in treating infections caused by yeasts / moulds

Country Status (14)

Country Link
EP (1) EP3197476A1 (en)
JP (1) JP2017532317A (en)
KR (1) KR20170052613A (en)
CN (1) CN106687140A (en)
AU (1) AU2015323566B2 (en)
BR (1) BR112017005272A2 (en)
CA (1) CA2959003A1 (en)
GB (1) GB201416727D0 (en)
MX (1) MX2017003550A (en)
NZ (1) NZ730092A (en)
RU (1) RU2017108196A (en)
SG (1) SG11201701648UA (en)
WO (1) WO2016046524A1 (en)
ZA (1) ZA201701330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004485A1 (en) 2015-07-02 2017-01-05 Raptor Pharmaceuticals Inc. Ado-resistant cysteamine analogs and uses thereof
EP3573994A4 (en) * 2017-01-25 2020-11-11 Adare Pharmaceuticals, Inc. Cysteamine prodrugs
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
EP3866775A1 (en) * 2018-10-17 2021-08-25 Novabiotics Limited Dosage regime
CN110551637B (en) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 Echinospora echinocandii from radix astragali root for efficiently inhibiting botrytis cinerea and application thereof
CN110859950B (en) * 2019-11-25 2021-08-10 武汉大学 Pharmaceutical composition for candida albicans echinocandin drug-resistant bacteria and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
PT1778720E (en) * 2004-08-18 2010-11-29 Novabiotics Ltd Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
JP2006347989A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
JP2006347990A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
CA2764236A1 (en) * 2009-08-13 2011-02-17 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
WO2016046524A1 (en) 2016-03-31
EP3197476A1 (en) 2017-08-02
KR20170052613A (en) 2017-05-12
AU2015323566B2 (en) 2018-03-22
NZ730092A (en) 2018-05-25
MX2017003550A (en) 2017-07-28
SG11201701648UA (en) 2017-04-27
CA2959003A1 (en) 2016-03-31
RU2017108196A (en) 2018-10-24
BR112017005272A2 (en) 2017-12-12
JP2017532317A (en) 2017-11-02
RU2017108196A3 (en) 2019-06-19
AU2015323566A1 (en) 2017-04-06
CN106687140A (en) 2017-05-17
GB201416727D0 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HRP20192119T8 (en) Composition and method for aiding sleep
HUE047226T2 (en) Moulding body and method for its production
SG11201609652RA (en) Treatment of polybacterials infections
ZA201701330B (en) Use of cysteamine in treating infections caused by yeasts / moulds
SG11201702688UA (en) Methods of treating rsv infections
GB201416006D0 (en) Organotypic skin model
GB201416102D0 (en) Impovements In or Relating To Shower Rods
HK1225994A1 (en) Compositions for use in the treatment of allergic conditions
ZA201608607B (en) Novel fluoroquinolones and use thereof to treat bacterial infections
GB201405013D0 (en) Improvements in or relating to manufacture of packaging
IL249152A0 (en) Botulinum toxin for use in the treatment of paratonia
IL249616A0 (en) Methods for treating infections
IL251040A0 (en) Use of cysteamine in treating infections caused by yeasts/moulds
GB201709068D0 (en) Improvements in and relating to servo valves
PT3160263T (en) Compositions and methods for preventing infections
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB201521802D0 (en) Mould treatment
GB201410990D0 (en) General cure to diseases